7,8-Dihydroxyflavone for Health & Longevity

Evidence Review created on 09/17/2026 using AI4L / Opus 5

Also known as: 7,8-DHF, Tropoflavin, 7,8-Dihydroxy-2-phenyl-4H-chromen-4-one

Motivation

7,8-Dihydroxyflavone (tropoflavin) is a small plant flavone found in the leaves of a few tropical and alpine species. Interest in it rests on one striking claim: given orally, it crosses into the brain and switches on the same docking point that a natural growth protein uses to keep nerve cells alive and connected.

That protein itself cannot be given as a medicine, because it breaks down too fast and does not reach the brain from the bloodstream, so a small, orally active stand-in has obvious appeal. The compound emerged from a laboratory screen about fifteen years ago, has since been through hundreds of animal experiments, and is now sold directly to consumers as a capsule or powder. Whether it really acts where it is said to act is openly disputed, and a second, unrelated enzyme target was described more recently.

This review examines what the evidence supports for adults trying to protect brain and metabolic function with age: how the compound is thought to work, which effects have been recorded and in which species, what is known about its safety, and how the absence of human studies bears on all of it.

Benefits - Risks - Protocol - Conclusion

Grokipedia

Tropoflavin

The dedicated entry, covering chemistry, plant sources, the receptor mechanism and the newer phosphatase target, and stating plainly that clinical translation has not moved past preclinical work.

Examine

7,8-Dihydroxyflavone

Examine’s entry states directly that the cognitive and motor claims rest on animal evidence and that no human evidence exists to date, a useful independent check against marketing copy.

ConsumerLab

No ConsumerLab article covering 7,8-Dihydroxyflavone exists. A direct search of the site returns only unrelated recalls, surveys and news releases, and the compound has never been included in a ConsumerLab testing programme.

Systematic Reviews

No systematic reviews or meta-analyses for 7,8-Dihydroxyflavone were found on PubMed as of September 17, 2026.

Both arms of this intervention’s central trade-off are therefore unrepresented: neither the claimed cognitive and metabolic benefit nor the principal risk, the off-target activity of an unstudied catechol flavone, has been the subject of a systematic review or meta-analysis. The 396 indexed records are preclinical primary studies and narrative reviews.

Mechanism of Action

7,8-Dihydroxyflavone carries two adjacent hydroxyl groups on one ring, a catechol arrangement that drives both its proposed receptor activity and its chemical instability. The original account holds that it binds the outer domain of TrkB, forces two receptor copies together and triggers self-phosphorylation, switching on the PI3K/Akt (a cell-survival signalling cascade) and MAPK/ERK (a growth and plasticity cascade) routes BDNF itself uses, selectively over the related receptors TrkA and TrkC (Jang et al., 2010).

A competing account exists. An assay panel that reproduced BDNF’s own effects could not reproduce receptor activation with the flavone at any concentration (Boltaev et al., 2017), and a lung study found its antifibrotic action persisted when TrkB was pharmacologically blocked (Song et al., 2026). Crystallography then confirmed a distinct target: the compound inhibits pyridoxal phosphatase (the enzyme that destroys the active form of vitamin B6), raising pyridoxal 5’-phosphate inside neurons (Brenner et al., 2024). It also activates Nrf2 (the master switch for antioxidant genes) (Kang et al., 2015) and transactivates estrogen receptor α (Zhao et al., 2021).

In rodents it is orally absorbed and distributes to brain, skeletal muscle and liver, but oral bioavailability is roughly 5% and plasma half-life about two hours. Clearance runs through glucuronidation by UGT enzymes (which attach a sugar acid so a compound can be excreted) and catechol methylation by COMT (catechol-O-methyltransferase, which caps catechols). Those limits prompted ester prodrugs (Chen et al., 2018).

Historical Context & Evolution

7,8-Dihydroxyflavone had no original therapeutic use. It existed as a laboratory flavone, one of many catechol-bearing compounds characterised for antioxidant chemistry, until a cell-based screen at Emory University picked it out of a compound library as the strongest apparent activator of TrkB (Jang et al., 2010). That screen was run by Keqiang Ye’s group, which went on to patent the molecule and its derivatives; nearly all of the foundational efficacy work carries that financial interest.

Its migration into health optimisation followed from the biology of BDNF rather than from the flavone. BDNF rises with aerobic exercise and falls with age, obesity and depression, which made it a favoured longevity target. The protein cannot be dosed, so an orally active stand-in was commercially inevitable, and derivative chemistry began within months (Liu et al., 2010).

Scientific standing has since moved in both directions. Ye’s group reported receptor dimerisation, reduced amyloid deposition, preserved hippocampal synapses and rescued memory in transgenic mice (Zhang et al., 2014). An independent panel later measured no receptor activation in several cell systems (Boltaev et al., 2017); that work did not repeat the animal endpoints, so the behavioural findings stand unexplained rather than reversed. A 2024 crystallographic study supplied a second, unambiguous target (Brenner et al., 2024), which reframes the dispute rather than closing it.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: there is no human clinical endpoint and no validated clinical surrogate measured on this compound in a single trial, let alone in more than one.

Medium 🟩 🟩

Nothing reaches Medium either: no single human trial and no observational human cohort has measured any outcome on this compound.

Low 🟩

Speculative 🟨

Learning and Memory in Aging

Aged rats regain spatial memory after dosing (Zeng et al., 2012), and dendrite growth on new neurons is restored (Wang et al., 2017). No human cognitive study exists.

Depressive and Anxiety-Like Behaviour ⚠️ Conflicted

Chronic dosing restores pleasure-seeking in stressed mice (Zhang et al., 2016). A comparison found the effect briefer than ketamine’s, with no rise in synaptic proteins (Zhang et al., 2015). Net: inconsistent and unreplicated.

Alzheimer’s-Type Brain Pathology

Oral dosing in transgenic mice lowered amyloid deposition, preserved hippocampal synapses and prevented memory loss (Zhang et al., 2014). Findings come largely from the patent-holding laboratory. No human study exists.

Dopamine Neuron Survival and Motor Function

In mice and monkeys given a nerve-toxin that destroys dopamine neurons, dosing preserved those neurons and reduced movement deficits (Zuo et al., 2021; He et al., 2016). No human study exists.

Body Composition and Insulin Sensitivity

In female mice fed a fatty diet, dosing raised UCP1 (a heat-generating protein) and AMPK (the cell’s energy sensor) in muscle, cutting fat mass (Chan et al., 2015). Male mice did not respond.

Muscle Mitochondrial Quality Control

Feeding the compound increased mitochondrial content and mitophagy, the clearance of damaged mitochondria, in mouse skeletal muscle (Ahuja et al., 2022). This is a tissue measurement, not a functional outcome.

Cellular Antioxidant Defence

The compound drives Nrf2 into the nucleus and raises HO-1 (heme oxygenase-1, a protective enzyme) in cultured skin cells (Ryu et al., 2014) and muscle cells (Kang et al., 2015). Cell culture only.

Cochlear Synapse Preservation

Delivered into the cochlea, the compound regenerated hearing-nerve synapses lost to noise in mice (Fernandez et al., 2021), extending earlier survival work (Yu et al., 2013). Local surgical delivery, not oral dosing.

Cardiomyocyte Protection During Chemotherapy ⭕️ Not Central to Health & Longevity

Heart cells exposed to cisplatin or etoposide survived better with pretreatment (Tian et al., 2025; Hu et al., 2026). This bears on chemotherapy tolerance, not healthy aging. Cultured cells only.

Benefit-Modifying Factors

COMT and UGT1A polymorphisms: COMT and UGT1A (a family of glucuronidation enzymes) clear the compound. Low-activity variants would raise exposure and high-activity variants lower it. No pharmacogenetic study exists, so this is inference from the clearance pathway.
Baseline vitamin B6 and BDNF status: the confirmed enzyme target raises the active form of vitamin B6. Anyone already replete, or already high in BDNF from regular aerobic training, has less headroom than someone deficient or sedentary.
Sex: the metabolic benefit in mice was female-specific and disappeared without muscle estrogen receptor α (Zhao et al., 2021). Male mice on the same protocol showed no fat loss, so sex may gate this effect entirely.
Pre-existing conditions: insulin resistance, obesity and depression are the states in which BDNF signalling is measurably low, and are therefore where any real effect should be largest. Metabolically healthy, non-depressed adults have the least to gain.
Age: effects in rats were stronger at 22 months than at 30 months, and the oldest animals needed longer dosing for a smaller gain (Zeng et al., 2012). Later starts appear to yield less.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: no human adverse-event record, trial safety report or validated clinical surrogate exists for this compound in more than one trial.

Medium 🟥 🟥

Nothing reaches Medium either: no single human trial and no observational human safety series has measured any adverse outcome on this compound.

Low 🟥

Speculative 🟨

Vitamin B6 Pathway Disruption

The compound inhibits pyridoxal phosphatase, raising pyridoxal 5’-phosphate in neurons (Brenner et al., 2024). Sustained elevation of this cofactor underlies pyridoxine-induced sensory nerve damage. The basis is mechanistic only.

Seizure-Threshold Effects and Dose Reversal

In a rat epilepsy model, 5 mg/kg suppressed later spontaneous seizures while 10 mg/kg did not (Guarino et al., 2022). A benefit that inverts across a twofold step cannot be titrated safely.

Estrogen Receptor Activation

The compound phosphorylates and transactivates estrogen receptor α at two regulatory sites (Zhao et al., 2021). In hormone-sensitive tissue this is an unwanted growth signal. No human exposure data exist.

Tumour Promotion Through TrkB Signalling

TrkB and BDNF are most strongly expressed in aggressive neuroblastomas, a childhood nerve-tissue cancer (Aygun, 2018, a review). Chronically activating that receptor in someone harbouring such a tumour is a theoretical hazard.

Catechol Oxidation and Reactive Quinone Formation

The adjacent hydroxyl pair that makes the compound an antioxidant also oxidises readily, forming reactive quinones that bind proteins and consume glutathione. No genotoxicity assay has been published.

Overstimulation and Disrupted Sleep

The claimed action increases excitatory synaptic signalling and plasticity (Jang et al., 2010), which plausibly interferes with sleep onset when dosed late. The basis is mechanistic and isolated user reports.

Risk-Modifying Factors

Genetic variants: slow COMT or reduced UGT1A activity would prolong exposure to the parent catechol, raising every dose-dependent hazard. Fast metabolisers face the reverse. Untested, so this is inference from the clearance route.
Baseline biomarkers: a high baseline pyridoxal 5’-phosphate, or regular high-dose pyridoxine supplementation, compounds the enzyme-inhibition risk. A raised fasting estradiol adds to the estrogen-receptor concern.
Sex: the estrogen-receptor interaction makes premenopausal women and anyone on hormone therapy the group most exposed to the hormonal risk, while the metabolic effects appear in female rodents only.
Pre-existing conditions: hormone-receptor-positive cancer, neuroblastoma, active epilepsy, peripheral nerve damage, and liver or kidney impairment that slows clearance all shift the risk profile unfavourably. None has been studied here.
Age: older adults clear glucuronidated compounds more slowly, are more likely to be on multiple prescriptions, and carry higher background prevalence of undetected hormone-sensitive tumours, all of which raise exposure and consequence.

Key Interactions & Contraindications

TRK-inhibitor cancer drugs (larotrectinib, entrectinib): absolute contraindication. These drugs are prescribed to shut down the exact receptor this compound is said to activate; concurrent use is direct pharmacological opposition, with loss of tumour control as the consequence.
Hormone-blocking therapy: tamoxifen, aromatase inhibitors (anastrozole, letrozole): absolute contraindication. Estrogen receptor α transactivation opposes the intended blockade, risking disease progression. No dose separation mitigates a receptor-level conflict.
Antidiabetic drugs (metformin, glipizide, insulin): caution, with hypoglycaemia (abnormally low blood sugar) as the consequence of additive glucose lowering. Mitigation: daily fingerstick glucose for the first two weeks, with prescriber-led adjustment of the prescribed agent.
Glucose-lowering supplements (berberine, alpha-lipoic acid, chromium picolinate): caution, same additive hypoglycaemia risk. Mitigation: a single glucose-active agent introduced at a time, separated by at least two weeks, with glucose measurement in between.
Vitamin B6 supplements (pyridoxine, pyridoxal 5’-phosphate) and B6-depleting drugs (isoniazid, penicillamine): caution, with sensory nerve damage as the consequence. Mitigation: total supplemental pyridoxine held below 10 mg daily.
COMT-competing drugs (levodopa, entacapone, tolcapone): monitor. All are catechols competing for the same methylating enzyme, so exposure may rise unpredictably. Mitigation: doses separated by four hours, watching for dyskinesia (involuntary movements) or blood-pressure change.
Over-the-counter acetaminophen: caution. Both compete for sulfation and glucuronidation, the pathways that keep acetaminophen’s toxic metabolite in check, with liver injury as the consequence. Mitigation: avoidance above 2 g acetaminophen daily.
Other catechol and flavonoid supplements (quercetin, luteolin, myricetin, green tea catechins): monitor. Shared conjugation pathways mean stacking raises systemic exposure to all of them. Mitigation: no simultaneous full-dose stacking of multiple flavonoids.
Antiepileptic drugs (levetiracetam, valproate, lamotrigine): caution, with loss of seizure control as the consequence, since receptor activation shifts seizure threshold in both directions in animals. Mitigation: avoidance where epilepsy is not fully controlled.
Aerobic exercise and sauna: monitor only — additive rather than adverse, with a smaller-than-expected supplement effect as the consequence. Both raise endogenous BDNF, so any real benefit may already be present in trained individuals. No mitigation is needed.

Populations who should avoid 7,8-Dihydroxyflavone:

Anyone with a current or prior hormone-receptor-positive cancer (estrogen receptor-positive breast or endometrial cancer, defined as 1% or more nuclear staining)
Anyone with a neuroblastoma or an NTRK-fusion tumour (a cancer driven by a fused neurotrophic receptor gene), whether treated or in surveillance
Anyone with epilepsy that is not fully controlled, defined as one or more seizures in the previous 12 months
Anyone with established peripheral sensory nerve damage, or taking more than 50 mg daily of supplemental pyridoxine
Anyone with advanced liver disease (Child-Pugh Class B or C, a severity score for cirrhosis) or an estimated filtration rate below 30 mL/min/1.73 m² (a measure of kidney filtering capacity)
Anyone pregnant, attempting conception, or breastfeeding
Anyone under 18 years of age

Risk Mitigation Strategies

Lowest marketed starting dose: 25 mg once daily for at least four weeks before any increase. A twofold step reversed the benefit in the rat seizure model, so slow escalation limits that reversal.
Capped total vitamin B6 intake: supplemental pyridoxine held below 10 mg daily, with plasma pyridoxal 5’-phosphate measured at baseline and 12 weeks. This mitigates the sensory nerve damage created by inhibiting the clearing enzyme.
Morning-only dosing: the single daily dose before 10:00, given a roughly two-hour half-life and a mechanism that raises excitatory signalling. This mitigates sleep-onset disruption without reducing daytime exposure.
Screening before first use, not after: an age-appropriate cancer screen, and in women a current mammogram. This mitigates the hormone-receptor and receptor-activation hazards, which are unrecoverable once a tumour is being stimulated.
Single-variable trial design: nothing else changed for the first 12 weeks, and no second flavonoid or glucose-active supplement added. This mitigates additive hypoglycaemia and the inability to attribute any adverse effect.
Low threshold for stopping on sensory symptoms: discontinuation at the first tingling, numbness or burning in hands or feet. Pyridoxine-induced nerve damage is reversible early and can become permanent if dosing continues.
Time-boxed exposure: a fixed 12-week stop date set in advance with defined success criteria. This mitigates open-ended exposure to a compound with no chronic human safety data.

Therapeutic Protocol

No clinical protocol exists: no clinic or practitioner group prescribes this compound, because it has never been trialled in humans. Everything below is reconstructed from supplement labelling and from the rodent dosing established by Keqiang Ye’s Emory laboratory.
Consumer dose range: capsules are sold at 25 mg, and self-administered regimens typically run 25–50 mg once daily. No dose-finding study supports any of these figures.
Rodent-equivalent framing: the workhorse preclinical dose is 5 mg/kg in mice, which does not translate directly to a human milligram figure. Any body-weight conversion is extrapolation without pharmacokinetic support.
Competing approach, parent compound: the flavone itself carries roughly 5% oral bioavailability and a two-hour half-life, in exchange for availability and a natural-product origin.
Competing approach, derivatives: ester prodrugs such as R13 and the fluorinated analogue CF₃CN were built specifically to fix that exposure problem (Chen et al., 2021). Neither is available to consumers.
Best time of day: morning, before 10:00. The short half-life means late dosing adds no meaningful overnight exposure while risking sleep disruption from raised excitatory signalling.
Half-life: roughly two hours in plasma in rodents, with brain concentrations falling in parallel. Human half-life has never been measured.
Single versus split dosing: the short half-life argues mechanically for splitting, but the plasticity effects in animals followed once-daily dosing, so single morning dosing is the only regimen with supporting precedent.
Genetic polymorphisms: slow COMT or reduced UGT1A activity raises exposure from any given dose. No pharmacogenetic dosing guidance exists, so for carriers the low end of the range functions as a ceiling.
Sex differences: the metabolic effects in mice appeared only in females and required muscle estrogen receptor α. Men should not expect the body-composition effect; hormone-sensitive history excludes use entirely.
Age considerations: benefit in rats fell sharply between 22 and 30 months of age. Adults past 75 face less effect, slower clearance, and a higher chance of an interacting prescription.
Baseline biomarkers: fasting insulin, fasting glucose and plasma pyridoxal 5’-phosphate set the starting point against which any change is judged. Without them, no response is distinguishable from drift.
Pre-existing conditions: insulin resistance and low mood are where any real effect should be largest; hormone-sensitive disease, uncontrolled epilepsy and nerve damage exclude use entirely.

Discontinuation & Cycling

Not a lifelong intervention: nothing supports indefinite use. With no chronic human safety data and no documented long-term benefit, open-ended dosing accumulates unmeasured risk against an unmeasured return.
No withdrawal syndrome described: no rebound, dependence or discontinuation effect has been reported in any animal study or user account. The compound can be stopped without tapering.
Tapering not applicable: given a two-hour half-life and no receptor downregulation data, abrupt cessation carries no known hazard, and no tapering schedule has ever been proposed or tested.
Cycling as risk control, not efficacy maintenance: no tolerance has been demonstrated, so cycling is not needed to preserve effect. A 12-weeks-on, 4-weeks-off pattern nonetheless limits cumulative exposure.
Defined stopping signals: discontinuation rather than dose reduction is the response to any new sensory symptom in hands or feet, new insomnia, or a low-blood-sugar episode.

Sourcing and Quality

Research-chemical supply chain: this is not a mainstream supplement. Most material originates from bulk chemical synthesis, and purity rather than potency is the dominant quality question, since the catechol degrades on exposure to air and light.
Certificate of analysis: the minimum verification is a batch-specific certificate showing identity by high-performance liquid chromatography, assay purity above 98%, and residual solvent and heavy-metal testing. Without it, capsule contents are unverifiable.
Third-party testing as the deciding criterion: vendors publishing independent laboratory results per lot are distinguishable from those offering only a supplier’s own specification sheet. No regulator verifies these products.
Reputable suppliers: Nootropics Depot is the most established retailer publishing per-batch third-party identity and purity testing. Bulk research-chemical vendors selling without lot documentation offer no such assurance.
Formulation and storage: 25 mg capsules are more accurately dosed than loose powder, where a two-milligram weighing error is proportionally large. Sealed, dry, light-protected storage slows catechol oxidation.
No compounding pharmacy route: because the compound is not a licensed drug, compounding pharmacies will not prepare it, and no pharmaceutical-grade human formulation exists anywhere.

Practical Considerations

Time to effect: unknown in humans. Animal work suggests days for mood-related endpoints and two to four weeks of daily dosing for memory and metabolic changes, so 12 weeks is the shortest informative window.
Common pitfall, stacking: adding it to an existing multi-supplement regimen makes any effect or adverse event unattributable. With no reference safety profile, attribution is the only available tool.
Common pitfall, dose escalation: the assumption that more is better contradicts the one dose-response dataset available, in which doubling the dose abolished the benefit.
Common pitfall, exercise substitution: treating the compound as a replacement for aerobic training inverts the evidence, since exercise is the only intervention with human data on the pathway it targets.
Regulatory status: sold in the United States as a dietary supplement without pre-market safety or efficacy review. It is not approved as a drug anywhere, and no marketing authorisation has been sought.
Cost and accessibility: inexpensive, roughly 20 to 40 US dollars for a month at 25 mg daily, and available online without prescription. Cost is not a barrier; verified quality is.
Structural funding bias: the parent compound is unpatentable and cheap, while its derivatives are patented. Neither insurers nor developers have an incentive to fund trials of the cheap version, which is part of why human data exist for neither.

Interaction with Foundational Habits

Sleep: potentiating in the wrong direction if dosed late. The proposed mechanism raises excitatory synaptic signalling, and the two-hour half-life means an evening dose delivers its peak near bedtime without extending overnight coverage. Practical handling: dosing before 10:00, never within eight hours of sleep.
Nutrition: direct interaction with vitamin B6 status. The confirmed enzyme target controls the active form of B6, so high-dose pyridoxine supplements, fortified energy drinks and B-complex products stack with it. Absorption of the flavone itself improves with a fat-containing meal, given poor water solubility.
Exercise: overlapping rather than additive. Aerobic training is the best-established way to raise BDNF in humans, and rodent data show the compound and exercise converge on the same muscle and hippocampal endpoints (Ahuja et al., 2022). Trained individuals have less headroom for any added effect.
Stress management: indirect and unmeasured. Chronic stress lowers BDNF, and the animal antidepressant-like effects were demonstrated in stress models (Zhang et al., 2016), implying the largest signal in chronically stressed states. No cortisol measurement has been reported in any study.

Monitoring Protocol & Defining Success

Because no human safety profile exists, baseline testing carries more weight here than for a studied compound: it fixes the reference values against which any change is read, and it screens for the conditions that exclude use. Baseline work before a first dose covers plasma pyridoxal 5’-phosphate, liver enzymes, fasting glucose and insulin, a high-sensitivity inflammation marker, sex hormones and a complete blood count, alongside an age-appropriate cancer screen. The ongoing cadence repeats the full panel at 12 weeks, the point at which a trial is either extended on evidence or stopped; then at 6 months if use continues; then every 6 to 12 months thereafter. Vitamin B6 and fasting glucose sit on a shorter leash, adding a 4-week check and a further check at any dose change.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
Plasma pyridoxal 5’-phosphate	30–110 nmol/L	The compound blocks the enzyme that clears it; excess damages sensory nerves	The active form of vitamin B6. Fasting not required; supplemental pyridoxine held for 24 hours before the draw; best paired with homocysteine
ALT and AST	ALT 10–26 U/L (men), 10–19 U/L (women); AST 10–26 U/L	Catechol flavones are cleared hepatically; detects liver strain early	ALT is alanine aminotransferase and AST is aspartate aminotransferase, two liver enzymes. Conventional labs call anything under 40 U/L normal, which is far looser. Fasting draw
Fasting glucose	75–86 mg/dL	Rodent data show glucose lowering; detects additive low blood sugar	12-hour fast; drawn with insulin from the same sample; the conventional threshold for concern is 100 mg/dL
Fasting insulin	2–5 µIU/mL	The primary readout of the claimed metabolic benefit	Conventional ranges extend to 25 µIU/mL. Paired with glucose to derive HOMA-IR, a simple index of insulin resistance
HbA1c	4.8–5.3%	Confirms whether any glucose change holds over three months	HbA1c is glycated haemoglobin, a three-month average of blood sugar. The conventional threshold is 5.7%. Falsely low when red cells are short-lived
hs-CRP	Below 0.5 mg/L	Tests the anti-inflammatory claim made for the compound	hs-CRP is high-sensitivity C-reactive protein, a general inflammation marker. Repeated if any infection occurred within two weeks; the conventional cut-off is 3.0 mg/L
Estradiol; total testosterone in men	No established target on this compound; the change from the individual’s own baseline is what is tracked	The compound activates the estrogen receptor, so a shift matters more than an absolute value	Day 3 of the cycle in premenopausal women; morning draw for testosterone; same timing at every repeat
Complete blood count with differential	No functional target specific to this compound; the change from the individual’s own baseline within conventional limits is what is tracked	A broad safety net where no toxicity data exist	A complete blood count measures red cells, white cells and platelets. Drawn alongside the metabolic panel; no fasting required

Qualitative markers tracked alongside the laboratory panel:

Sleep onset latency and number of night wakings, recorded nightly for the first two weeks
Subjective energy and afternoon fatigue, scored daily on a fixed scale
Cognitive clarity, word-finding and short-term recall, judged against a fixed weekly task rather than impression
Mood and loss of interest in normally enjoyable activities, scored weekly with the same instrument each time
Any tingling, numbness or burning in hands or feet, recorded as present or absent daily
Training capacity and recovery, tracked through existing workout logs rather than recall

Emerging Research

First randomised trial of any small-molecule TrkB agonist: MT200605, an intravenous receptor agonist, is in a placebo-controlled Phase 2 study of 360 patients with acute ischaemic stroke, with disability at 90 days as the primary endpoint (NCT07205328). It is a different molecule, not 7,8-Dihydroxyflavone.
No registered trial of the compound itself: a ClinicalTrials.gov search returns no interventional or observational study of 7,8-Dihydroxyflavone in any indication. Until one is registered, every human claim remains extrapolation from rodents.
Prodrug programme: ester and fluorinated derivatives were built to raise oral exposure and brain penetration, with chronic dosing reported as non-toxic in mice (Chen et al., 2018; Chen et al., 2021). Success there would strengthen the target while sidelining the parent compound.
Mitochondrial mechanism for the derivatives: proteomic work found the prodrug raised oxidative phosphorylation and mitochondrial biogenesis in Alzheimer’s-model mice (Li et al., 2022). This could either broaden the longevity case or relocate it away from the receptor.
Second target under active study: the pyridoxal phosphatase finding (Brenner et al., 2024) opens a testable question, namely whether cognitive effects track vitamin B6 handling rather than receptor signalling. A negative answer would relabel the compound rather than weaken it.
Findings that could weaken the case: no receptor activation in a quantitative assay panel (Boltaev et al., 2017), no protection in ischaemic retinopathy (Zaitoun et al., 2021), and antifibrotic action persisting when the receptor is blocked (Song et al., 2026).
Genetic models to resolve the mechanism: a rat carrying two engineered BDNF cleavage-site mutations responded behaviourally to the compound (Xue et al., 2026). Models like this separate receptor-dependent from receptor-independent effects better than pharmacology alone.
Delivery reformulation: lipid nanoparticles for intranasal, nose-to-brain delivery were characterised in 2026 (Salamone et al., 2026). If exposure is the limiting factor, reformulation rather than new chemistry may change the answer.

Conclusion

7,8-Dihydroxyflavone is a plant flavone sold as a supplement on the strength of a single idea: that it stands in for a growth protein the brain uses to keep nerve cells alive and connected. Across fifteen years and several hundred animal experiments, the recorded effects are wide-ranging, covering memory in aged rodents, mood in stressed mice, body fat and insulin handling in female mice, cell protection in culture, and hearing-nerve repair after noise.

None of this has been tested in a person. There is no trial, no registered study, no safety report and no dosing data in humans, which is why every claimed benefit and every identified hazard in this review sits at the lowest evidence grade. That is a statement about what has been measured, not a verdict on the molecule.

Two further things weigh on the reading. Most of the foundational work comes from the laboratory that patented the compound and its derivatives, an independent group could not reproduce the receptor activation the whole story rests on, and a different enzyme target has since been confirmed. Separately, the parent compound is unpatentable and cheap, so neither insurers nor commercial developers have reason to fund the human trials that would settle it. The plausible hazards are real but unquantified: interference with vitamin B6 handling, activation of estrogen signalling, and a dose response that reversed direction in the one animal study that looked.

Top - Benefits - Risks - Protocol

7,8-Dihydroxyflavone for Health & Longevity

Motivation

Recommended Reading

Grokipedia

Examine

ConsumerLab

Systematic Reviews

Mechanism of Action

Historical Context & Evolution

Expected Benefits

High 🟩 🟩 🟩

Medium 🟩 🟩

Low 🟩

Speculative 🟨

Learning and Memory in Aging

Depressive and Anxiety-Like Behaviour ⚠️ Conflicted

Alzheimer’s-Type Brain Pathology

Dopamine Neuron Survival and Motor Function

Body Composition and Insulin Sensitivity

Muscle Mitochondrial Quality Control

Cellular Antioxidant Defence

Cochlear Synapse Preservation

Cardiomyocyte Protection During Chemotherapy ⭕️ Not Central to Health & Longevity

Benefit-Modifying Factors

Potential Risks & Side Effects

High 🟥 🟥 🟥

Medium 🟥 🟥

Low 🟥

Speculative 🟨

Vitamin B6 Pathway Disruption

Seizure-Threshold Effects and Dose Reversal

Estrogen Receptor Activation

Tumour Promotion Through TrkB Signalling

Catechol Oxidation and Reactive Quinone Formation

Overstimulation and Disrupted Sleep

Risk-Modifying Factors

Key Interactions & Contraindications

Risk Mitigation Strategies

Therapeutic Protocol

Discontinuation & Cycling

Sourcing and Quality

Practical Considerations

Interaction with Foundational Habits

Monitoring Protocol & Defining Success

Emerging Research

Conclusion